ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We next studied if the consistent lack of responses to TKIs in ex vivo drug testing was due to inability of TKIs to block cell signaling downstream of BCR-ABL1 in primary CP CML MNCs.